BPH - Benign Prostatic Enlargement

To compare incidence of new-onset depression, anxiety, suicidal ideation, and bipolar disorder among men with BPH treated with endoscopic outlet surgery versus medical management.

Using the TriNetX Research Network, we conducted a retrospective cohort study with two parallel 1:1 propensity score-matched (PSM) analyses comparing endoscopic outlet surgery (TURP, GreenLight PVP, laser enucleation of the prostate, or Aquablation) to (1) third-generation alpha-blocker monotherapy and (2) combination alpha-blocker/5α-reductase inhibitor therapy.

Advancements in surgical techniques have led to a shift in the types of procedures performed for BPH. This study aims to analyze trends in rates and outcomes of surgical procedures for BPH between 2008 and 2021.

Benign prostatic hyperplasia (BPH) is a common condition with trials that frequently rely on subjective outcomes. While federal regulations require prospective outcome registration in ClinicalTrials.

Prostate interventions are increasingly employed in management of benign prostatic hyperplasia (BPH) and prostate cancer. Routinely performed procedures include a widening array of surgical therapies for BPH, prostate needle biopsy, focal therapies, radical prostatectomy, and radiation therapy.

This study aimed to investigate the knowledge, attitude, and practice (KAP) regarding benign prostatic hyperplasia (BPH) among men aged 50 years and above.

A cross-sectional survey was conducted on men aged 50 years and above at four medical institutions in Beijing, China between July 1, 2023, and April 30, 2024.

Greenlight laser prostate photovaporization (PVP) is an alternative treatment for benign prostatic hyperplasia. However, compared to standard techniques such as transurethral resection of the prostate (TURP) and holmium laser prostate enucleation, it has certain limitations with respect to reintervention rates.

Detrusor underactivity (DUA) may coexist in up to one-third of men with BPH and LUTS, representing a particular challenge, as there are no universally agreed-upon criteria on the optimal method for diagnosing DUA, and no medical treatment is available.
In the recent era, as treatment options expand for surgical management of benign prostatic hyperplasia (BPH), prostatic urethral lift (PUL) remains a popular and in-demand option for patients looking for a minimally invasive option while sparing antegrade ejaculatory function. However, PUL failure can occur in inappropriately counseled patients such as those with prostates larger than 80cc and those with the presence of a median lobe. Retreatment rates after PUL, including return to medication therapy and secondary surgical therapy, are as high as 33.6%.

Transurethral resection of the prostate (TURP) is the gold standard for treating benign prostatic hyperplasia (BPH) but frequently causes retrograde ejaculation and bleeding. High-frequency irreversible electroporation (H-FIRE) is a non-thermal ablation technique offering tissue selectivity.

The frailty index (FI) is a well-established marker of biological aging and a widely validated predictor of adverse health outcomes in older adults. However, its association with symptomatic benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) has not been well defined in nationally representative populations.